Latest Headlines
Stereotactic radiation controls early stage lung cancer
Melanoma survivors at higher risk of other cancers
Cladribine and fludarabine equally helpful for progressive CLL
More frequent surveillance reduces colon cancer risk in Lynch syndrome families
Radiation can be avoided in early Hodgkin's lymphoma
NEWS PROVIDED BY 
VIEW ALL NEWSMerck vaccine wins U.S. OK for vaginal cancer
WASHINGTON (Reuters) - U.S. health regulators have approved Merck and Co's Gardasil vaccine to protect women against vaginal and vulvar cancers, the Food and Drug Administration said Friday.
The vaccine is already available in the United States to prevent cervical cancer and genital warts in girls and women ages 9 to 26 years old.
Gardasil was already approved for abnormal and precancerous vaginal and vulvar lesions, but the FDA said new evidence showed it benefited related cancers as well.
"There is now strong evidence showing that this vaccine can help prevent vulvar and vaginal cancers due to the same viruses for which it also helps protect against cervical cancer," said Jesse Goodman, director of the FDA's Center for Biologics Evaluation and Research.
The genetically engineered vaccine is effective against four strains of HPV.
"With additional one-year follow-up, we now have more rigorous data," said Rick Haupt, head of Merck's clinical research program for Gardasil.
However, the FDA, in a statement, cautioned that "no vaccine is 100 percent effective" and urged women to continue to receive routine screenings to detect possible cancer.
Common side effects from the vaccine include those seen with other injections such as fainting and injection pain as well as headache, nausea and fever, the FDA said.
Merck's Haupt also said the product's label was being updated to include additional reports of blood clots, autoimmune diseases and death in some patients who were given the vaccine.
So far more than 18 million Gardasil doses have been distributed in the United States, Haupt said.
Between 5,000 and 5,500 cases of vaginal and vulvar cancers are diagnosed in the United States each year, he said.
Copyright © 2008 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
NEWS PROVIDED BY
TEXT SIZE 